Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer

Inclusion Criteria: * Histology or cytology confirmed Non-small Cell Lung Cancer; EGFR mutation (EGFR 19del and/or 21L858R) detected by tumor tissue biopsy of primary lesion or metastatic lesion or plasma ctDNA * No previous anti-tumor treatment such as surgery, chemotherapy, radiotherapy or biological therapy * Stage IIIA N2 NSCLC according to the pathological evidence of endobronchial ultrasound(EBUS) or PET-CT, the short-axis diameter of lymph node 1-2cm, and considered surgically resectable at baseline by the surgical oncologist * Sufficient tumor histological specimens (non-cytology) for molecular marker analysis * At least one lesion with measurable diameter and its longest diameter is large than 10 mm by CT measurement Exclusion Criteria: * Previous systemic anti-tumor treatment of Non-small Cell Lung Cancer, including cytotoxic drug therapy, targeted drug therapy (tyrosine kinase inhibitors or monoclonal antibodies) and experimental treatment, etc * Previous local radiotherapy of Non-small Cell Lung Cancer * Be allergic to any component of Icotinib tablet (Conmana) * Other cancers within five years prior to the treatment of this study. Except for cervical carcinoma, basal cell carcinoma and bladder epithelial neoplasm (including Ta and Tis) * Any instable systemic disease, including: active infection, high blood pressure out of control, unstable angina, onset of angina pectoris within the past 3 months, congestive heart failure, myocardial infarction, severe arrhythmia, liver, kidney or metabolic disease * Previous interstitial lung disease, drug-induced interstitial disease, radiation pneumonia requiring hormone therapy or any active intersexual lung disease with clinical evidence * Idiopathic pulmonary fibrosis detected by CT scan at baseline; * Not fully controlled eye inflammation or infections, or any condition that may lead to the above eye diseases * Human immunodeficiency virus infection * Patients undergoing major surgery or severe trauma within 2 months prior to the first use of the experimental drug * Patients with Small Cell Lung Cancer * Pregnant or lactating women * Neurological or psychiatric disorders history, including epilepsy or dementia * Other situations not appropriate to enter the group considering by the investigators